Insider · CIK 0001922140
Jacob Ma-Weaver
Files at ORKA (ARCA biopharma, Inc.), LITS (MEI Pharma, Inc.). First filing -, latest -.
In brief
Jacob Ma-Weaver files SEC Form 4 as 10% owner and director at ORKA (ARCA biopharma, Inc.), and also at LITS (MEI Pharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jacob Ma-Weaver has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 29, 2024 | ORKA ARCA biopharma, Inc. | JOther Stock option (right to buy)derivative | -6,000 | - | - | 0 | Aug 30, 2024 |
| Aug 29, 2024 | ORKA ARCA biopharma, Inc. | JOther Stock option (right to buy)derivative | -6,000 | - | - | 0 | Aug 30, 2024 |
| Aug 29, 2024 | ORKA ARCA biopharma, Inc. | JOther Stock option (right to buy)derivative | -12,000 | - | - | 0 | Aug 30, 2024 |
| Jan 30, 2024 | ORKA ARCA biopharma, Inc. | AGrant or award Stock option (right to buy)derivative | +6,000 | $0.00 | $0 | 6,000 | Jan 31, 2024 |
| Dec 16, 2022 | ORKA ARCA biopharma, Inc. | XIn-the-money exercise Common Stock | +1,420,000 | $2.50 | $3.5M | 4,000,452 | Dec 19, 2022 |
| Dec 15, 2022 | ORKA ARCA biopharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +6,000 | $0.00 | $0 | 18,000 | Dec 19, 2022 |
| Dec 16, 2022 | ORKA ARCA biopharma, Inc. | XIn-the-money exercise Put Optionderivative | -14,200 | $0.00 | $0 | 30,000 | Dec 19, 2022 |
| Dec 16, 2022 | ORKA ARCA biopharma, Inc. | EExpiration of short derivative Put Optionderivative | -300 | $0.00 | $0 | 0 | Dec 19, 2022 |
Questions about Jacob Ma-Weaver
Answered from the filings on this page, as of the latest one.
Is Jacob Ma-Weaver buying or selling?
Jacob Ma-Weaver has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jacob Ma-Weaver's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jacob Ma-Weaver has 0.
Where does Jacob Ma-Weaver file Form 4?
Jacob Ma-Weaver has filed Form 4 at ORKA (ARCA biopharma, Inc.); LITS (MEI Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.